Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Operating Leases (2020 - 2025)

Dare Bioscience (DARE) has disclosed Operating Leases for 6 consecutive years, with $898000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 36.04% year-over-year to $898000.0, compared with a TTM value of $898000.0 through Sep 2025, down 36.04%, and an annual FY2024 reading of $754383.0, down 19.38% over the prior year.
  • Operating Leases was $898000.0 for Q3 2025 at Dare Bioscience, up from $448206.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.5 million in Q2 2024 and bottomed at $23000.0 in Q2 2023.
  • Average Operating Leases over 5 years is $707658.7, with a median of $675191.5 recorded in 2021.
  • The sharpest move saw Operating Leases tumbled 98.0% in 2023, then surged 6530.43% in 2024.
  • Year by year, Operating Leases stood at $384000.0 in 2021, then crashed by 76.47% to $90346.0 in 2022, then soared by 935.73% to $935743.0 in 2023, then dropped by 19.38% to $754383.0 in 2024, then rose by 19.04% to $898000.0 in 2025.
  • Business Quant data shows Operating Leases for DARE at $898000.0 in Q3 2025, $448206.0 in Q2 2025, and $1.2 million in Q1 2025.